--- a
+++ b/clusters/9knumclustersv2/clust_1467.txt
@@ -0,0 +1,13 @@
+Has taken valproic acid, or another histone deacetylase inhibitor, within  weeks prior to study day 
+Patients taking any histone deacetylase inhibitor (HDACi) other than vorinostat
+Patients should not have taken valproic acid or another histone deacetylase inhibitor for at least  weeks prior to enrollment
+Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least  weeks of the date of first administration of study drug
+Prior treatment with a histone deacetylase inhibitor
+Participants should not have taken valproic acid or another histone deacetylase inhibitor for at least  weeks prior to study enrollment
+Patients should not have taken valproic acid or another histone deacetylase inhibitor for at least  weeks prior to enrollment
+CTCL disease that is known to be refractory to systemic histone deacetylase inhibitors
+Received immunomodulating agents, histone deacetylase inhibitors, cyclosporine, or mycophenolate within  weeks of screening
+Patients may not have taken another histone deacetylase inhibitor (i.e. valproic acid, vorinostat) for at least  weeks prior to enrollment
+Patients should not have taken valproic acid, another histone deacetylase (HDAC) inhibitor, for at least  weeks prior to enrollment
+Previous therapy with histone deacetylase inhibitor.
+For subjects assigned to take vorinostat, prior exposure to vorinostat or other known histone deacetylase (HDAC) inhibitors for cancer therapy; patients should not have taken valproic acid, another histone deacetylase inhibitor, for at least  weeks prior to study enrollment; note: this criterion does NOT apply to subjects treated on the Expansion Cohort (accruals post February , )